Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis

作者：Lisa M. Lundquist · 发表于：World Journal of Orthopedics · 年份：2014 · DOI：10.5312/wjo.v5.i4.504 · 被引用次数：46 · 研究领域：Rheumatoid Arthritis Research and Therapies、Autoimmune and Inflammatory Disorders Research、Systemic Lupus Erythematosus Research

Tofacitinib is the first in a new class of nonbiologic disease-modifying antirheumatic drugs (DMARDs), a targeted, synthetic DMARD, approved for the treatment of rheumatoid arthritis (RA) as monotherapy or in combination with methotrexate or other non-biologic DMARD. Tofacitinib, an orally administered Janus kinase (JAK) inhibitor, decreases T-cell activation, pro-inflammatory cytokine production, and cytokine signaling by inhibiting binding of type I cytokine receptors family and γ-chain cytokines to paired JAK1/JAK3 receptors. The net effect of tofacitinb's mechanism of action is decreased synovial inflammation and structural joint damage in RA patients. To date, six phase 3 trials have been conducted to evaluate the safety and efficacy of tofacitinib under the oral rheumatoid arthritis triaLs (ORAL) series. This review describes the pharmacology of the novel agent, tofacitinib, and details the safety and efficacy data of the ORAL trials.